NTHI Accelerates Brain Cancer Trials, Reports Promising NEO100 Data

TL;DR

**NTHI's promising early clinical data for NEO100 and strategic AI acquisition make it a speculative buy for aggressive biotech investors.**

AI Summary

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies. The company reported no commercial products or revenue in 2025, as its lead product candidates, NEO100 and NEO212, are still in clinical development. NEO100, a purified form of perillyl alcohol administered intranasally, is in Phase IIa trials for recurrent malignant glioma and skull-based meningioma. Combined analysis of Phase I, Phase IIa, and compassionate-use cohorts for NEO100 in 24 patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma showed a 21% radiographic response rate, exceeding historical <8%, and 44% achieved six-month progression-free survival, compared to historical 21–31%. NEO212, an oral bioconjugate of temozolomide and perillyl alcohol, completed its Phase I dose-escalation trial in Q4 2023, establishing a recommended Phase 2 dose of 610 mg, with preliminary observations suggesting anti-tumor activity. In 2025, NTHI acquired an AI-driven drug discovery and 3D bioprinting intellectual property portfolio for approximately $3.5 million, comprising $500,000 in cash and $3.0 million in common stock, to accelerate preclinical and clinical research. The company projects a readout for NEO100 Phase II studies by the end of 2024, a full year ahead of its original 2025 timeline.

Why It Matters

NEONC TECHNOLOGIES' progress in developing NEO100 and NEO212 offers a glimmer of hope for patients with aggressive brain cancers, a field notoriously difficult to treat due to the blood-brain barrier. The reported 21% radiographic response rate and 44% six-month progression-free survival for NEO100 significantly surpass historical benchmarks, potentially shifting treatment paradigms for recurrent high-grade gliomas. For investors, this clinical advancement, coupled with the strategic acquisition of AI-driven drug discovery tools for $3.5 million, signals a potential acceleration of their pipeline and enhanced competitive positioning against larger pharmaceutical players in the oncology space. Employees and customers could see a future where more effective, less toxic treatments are available, improving quality of life and extending survival for those facing dire prognoses.

Risk Assessment

Risk Level: high — NEONC TECHNOLOGIES is a clinical-stage biopharmaceutical company with no approved products or commercial revenue, as explicitly stated in the filing. The company's future depends entirely on the successful completion of clinical trials and regulatory approvals for its product candidates, which is a highly uncertain and lengthy process. The aggregate market value of non-affiliate common equity was approximately $67.9 million as of June 30, 2025, indicating a relatively small market capitalization for a company facing significant R&D costs and regulatory hurdles.

Analyst Insight

Investors should consider NTHI a high-risk, high-reward opportunity. Monitor the upcoming Type B End-of-Phase 1 meeting with the FDA for NEO212 and the projected end-of-2024 readout for NEO100 Phase II studies, as these milestones will be critical catalysts for future valuation. Given the lack of commercial products, any investment should be part of a diversified portfolio.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Key Numbers

• $67.9 million — Aggregate market value of common equity held by non-affiliates (as of June 30, 2025, indicating market capitalization)
• 23,806,216 — Shares of common stock outstanding (as of March 30, 2026)
• $3.5 million — Total purchase consideration for IP acquisition (in 2025, including cash and common stock)
• 21% — Radiographic response rate for NEO100 (in combined analysis of 24 patients, exceeding historical <8%)
• 44% — Six-month progression-free survival (PFS-6) for NEO100 (compared to historical 21–31% for recurrent IDH1-mutant high-grade glioma)
• 33% — Overall survival for NEO100 patients (8 of 24 patients remained alive for at least 18 months)
• 610 mg — Recommended Phase 2 dose (RP2D) for oral NEO212 (established after Phase 1 dose escalation)
• 2024 — Projected readout for NEO100 Phase II studies (advancing original timeline by a full year from 2025)

Key Players & Entities

• NEONC TECHNOLOGIES HOLDINGS, INC. (company) — registrant
• NTHI (company) — trading symbol
• FDA (regulator) — regulatory approval body
• NEO100 (company) — lead product candidate
• NEO212 (company) — second lead product candidate
• Quazar Investment Group (company) — strategic partnership
• Dr. Ishwar K. Puri (person) — joined Board of Directors
• University of Southern California (company) — preclinical study location
• Nasdaq Global Market (company) — exchange where common stock is registered

FAQ

Risk Factors

• Clinical Trial Risks [high — regulatory]: The company's success is heavily dependent on the successful development and regulatory approval of its product candidates, NEO100 and NEO212. Delays or failures in clinical trials, such as the ongoing Phase IIa trials for NEO100, could significantly impact the company's ability to generate revenue and achieve profitability. The projected readout for NEO100 Phase II studies by the end of 2024 is ahead of the original 2025 timeline, indicating potential acceleration but also inherent risks in meeting such accelerated targets.
• Lack of Commercial Revenue [high — financial]: As of the reporting period, NEONC TECHNOLOGIES HOLDINGS, INC. has no commercial products and reported no revenue in 2025. The company is reliant on continued funding to support its research and development activities for NEO100 and NEO212. The acquisition of AI-driven drug discovery and 3D bioprinting IP for $3.5 million in 2025, comprising $500,000 cash and $3.0 million in stock, further highlights the need for capital to advance its pipeline.
• Competition and Market Adoption [medium — market]: The biopharmaceutical market for intracranial malignancies is highly competitive. Even if NEO100 and NEO212 are approved, they will face competition from existing treatments and other pipeline drugs. The company's ability to achieve market adoption will depend on demonstrating superior efficacy and safety profiles compared to existing therapies, which is still under evaluation in ongoing clinical trials.
• Reliance on Key Personnel and Technology [medium — operational]: The company's development of novel drug delivery methods and product candidates like NEO100 and NEO212 relies on specialized expertise and intellectual property. Any disruption in key personnel or challenges in integrating the recently acquired AI-driven drug discovery and 3D bioprinting IP could impede progress.
• FDA Approval Uncertainty [high — regulatory]: The path to FDA approval for new drugs is complex and uncertain. The company's product candidates, NEO100 and NEO212, must successfully navigate rigorous clinical trials and regulatory review processes. The FDA's approval is not guaranteed, and any setbacks in the approval process could have severe financial and operational consequences.

Industry Context

NEONC TECHNOLOGIES HOLDINGS, INC. operates in the highly competitive clinical-stage biopharmaceutical sector, specifically targeting intracranial malignancies. This niche is characterized by significant unmet medical needs due to the challenges posed by the blood-brain barrier, leading to poor prognoses for patients. The industry is driven by innovation in drug discovery, novel delivery systems, and advancements in areas like AI-driven research, as evidenced by NTHI's recent IP acquisition. Companies in this space face long development cycles, high R&D costs, and stringent regulatory hurdles.

Regulatory Implications

The company's progress is intrinsically tied to regulatory approvals from bodies like the FDA. The development of NEO100 and NEO212 requires successful navigation of Phase II and potentially Phase III clinical trials. Any delays, adverse findings, or failure to meet regulatory endpoints could halt development and significantly impact the company's viability. The accelerated timeline for the NEO100 Phase II readout suggests a proactive approach to regulatory engagement.

What Investors Should Do

1. Monitor the upcoming NEO100 Phase II study readouts scheduled for the end of 2024.
2. Evaluate the integration and impact of the recently acquired AI and 3D bioprinting IP.
3. Track the progress of NEO212's Phase 2 development following the completion of its Phase 1 trial.
4. Assess the company's cash burn rate and future funding needs.

Key Dates

• 2023-Q4: Phase I dose-escalation trial for NEO212 completed — Established a recommended Phase 2 dose (610 mg) and provided preliminary observations of anti-tumor activity, paving the way for further development.
• 2023-07: Phase IIa trial for NEO100 in skull-based meningioma launched — Expands the investigation of NEO100 to a new indication, demonstrating the company's ability to receive FDA approval for Phase II trials rapidly (30 days).
• 2024-12-31: Projected readout for NEO100 Phase II studies — This accelerated timeline (a full year ahead of the original 2025 projection) provides investors with an earlier potential look at critical efficacy data for NEO100.
• 2025: Acquisition of AI-driven drug discovery and 3D bioprinting IP portfolio — Strategic move to enhance preclinical and clinical research capabilities, costing $3.5 million ($500,000 cash, $3.0 million stock), signaling investment in future growth.

Glossary

Intracranial malignancies

Aggressive cancers located within the skull, affecting the brain. (This is the primary focus of NEONC TECHNOLOGIES HOLDINGS, INC.'s drug development efforts, with lead candidates NEO100 and NEO212 targeting these difficult-to-treat cancers.)

Blood-brain barrier (BBB)

A protective barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system. (The BBB is a major challenge in treating brain cancers, as it prevents most drugs from entering the brain. NEONC's intranasal delivery method for NEO100 aims to bypass this barrier.)

Perillyl alcohol (POH)

A naturally occurring monoterpene found in plants like lavender and peppermint, being developed by NTHI as NEO100. (It is the active compound in NEO100, a lead product candidate for treating brain cancers, administered via intranasal delivery.)

Malignant glioma

A type of aggressive brain tumor that arises from glial cells, which support nerve cells. (NEONC is conducting Phase IIa trials for NEO100 in patients with recurrent malignant glioma, specifically WHO Grade III and IV, IDH1 mutant types.)

Meningioma

A tumor that arises from the meninges, the membranes that surround the brain and spinal cord. (NEONC is also conducting a Phase IIa trial for NEO100 in patients with malignant skull-based meningioma, an area with limited effective treatment options.)

Temozolomide

An oral chemotherapy drug commonly used to treat brain tumors like glioblastoma. (It is a component of NEO212, an oral bioconjugate drug candidate being developed by NTHI, combining it with perillyl alcohol.)

Radiographic response rate

The percentage of patients whose tumors shrink or disappear based on imaging scans (e.g., MRI, CT scans) after treatment. (A key metric for evaluating the efficacy of cancer treatments. NEO100 showed a 21% radiographic response rate in a combined analysis, exceeding historical benchmarks.)

Progression-free survival (PFS)

The length of time during and after treatment that a patient lives with the disease but it does not get worse. (A critical endpoint in cancer clinical trials. NEO100 demonstrated a 44% six-month progression-free survival rate in a specific patient group.)

Year-Over-Year Comparison

As NEONC TECHNOLOGIES HOLDINGS, INC. is a clinical-stage biopharmaceutical company with no commercial products, revenue figures are not applicable for year-over-year comparison. The company has advanced its pipeline, with NEO100 showing promising early-stage data (21% radiographic response rate, 44% PFS-6) and NEO212 completing Phase I trials. A significant development is the acquisition of AI and 3D bioprinting IP in 2025, indicating strategic investment in R&D capabilities. Furthermore, the projected acceleration of the NEO100 Phase II readout from 2025 to end-of-2024 suggests a more aggressive development timeline.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share NTHI The Nasdaq Global Ma
• $3.5 m — n for the transaction was approximately $3.5 million, including $500,000 in cash and $
• $500,000 — s approximately $3.5 million, including $500,000 in cash and $3.0 million in shares of o
• $3.0 million — million, including $500,000 in cash and $3.0 million in shares of our Common Stock valued at
• $25.00 — in shares of our Common Stock valued at $25.00 per share. The acquired technologies en

Filing Documents

• neonctechnologies_10k.htm (10-K) — 2065KB
• neonctechnologies_ex4-1.htm (EX-4.1) — 42KB
• neonctechnologies_ex14-1.htm (EX-14.1) — 70KB
• neonctechnologies_ex19-1.htm (EX-19.1) — 84KB
• neonctechnologies_ex23-2.htm (EX-23.2) — 3KB
• neonctechnologies_ex23-3.htm (EX-23.3) — 3KB
• neonctechnologies_ex31-1.htm (EX-31.1) — 16KB
• neonctechnologies_ex31-2.htm (EX-31.2) — 16KB
• neonctechnologies_ex32-1.htm (EX-32.1) — 6KB
• neonctechnologies_ex32-2.htm (EX-32.2) — 6KB
• neonctechnologies_ex97-1.htm (EX-97.1) — 44KB
• img_001.jpg (GRAPHIC) — 108KB
• img_002.jpg (GRAPHIC) — 38KB
• img_003.jpg (GRAPHIC) — 43KB
• img_004.jpg (GRAPHIC) — 60KB
• img_005.jpg (GRAPHIC) — 48KB
• img_006.jpg (GRAPHIC) — 49KB
• img_007.jpg (GRAPHIC) — 67KB
• img_008.jpg (GRAPHIC) — 31KB
• img_009.jpg (GRAPHIC) — 65KB
• img_010.jpg (GRAPHIC) — 37KB
• img_011.jpg (GRAPHIC) — 10KB
• img_012.jpg (GRAPHIC) — 26KB
• img_013.jpg (GRAPHIC) — 14KB
• img_014.jpg (GRAPHIC) — 27KB
• img_015.jpg (GRAPHIC) — 32KB
• img_016.jpg (GRAPHIC) — 38KB
• img_017.jpg (GRAPHIC) — 30KB
• img_018.jpg (GRAPHIC) — 27KB
• img_019.jpg (GRAPHIC) — 27KB
• 0001829126-26-002860.txt (&nbsp;) — 8750KB
• nthi-20251231.xsd (EX-101.SCH) — 56KB
• nthi-20251231_cal.xml (EX-101.CAL) — 45KB
• nthi-20251231_def.xml (EX-101.DEF) — 156KB
• nthi-20251231_lab.xml (EX-101.LAB) — 353KB
• nthi-20251231_pre.xml (EX-101.PRE) — 279KB
• neonctechnologies_10k_htm.xml (XML) — 632KB

Business

Item 1. Business 1

Risk Factors

Item 1A. Risk Factors 55

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 122

Cybersecurity

Item 1C. Cybersecurity 122

Properties

Item 2. Properties 124

Legal Proceedings

Item 3. Legal Proceedings 124

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 124 Part II 125

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 125

[Reserved]

Item 6. [Reserved] 125

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 126

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 139

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data F-1

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 140

Controls and Procedures

Item 9A. Controls and Procedures 140

Other Information

Item 9B. Other Information 141

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 141 Part III 142

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 142

Executive Compensation

Item 11. Executive Compensation 142

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 142

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 142

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 142 Part IV 143

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 143

Form 10-K Summary

Item 16. Form 10-K Summary 148 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, including the sections titled "Business", "Risk Factors", and "Management's Discussion and Analysis of Financial Condition and Results of Operations", contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about: the timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and developme

Business

Item 1. Business Overview Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain- malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates. NeOnc has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl alcohol ("POH") which is administered to brain cancer patients via intranasal delivery. Ongoing activities for intranasal delivery of NEO100: We have completed human testing in a Phase I clinical trial and are now conducting a Phase IIa trial with patients suffering from recurrent malignant glioma (WHO Grade III, IDH1 mutant, and WHO Grade IV, IDH1 mutant). Phase IIa trial of intranasal NEO100 (NEO 100-02) for patients with malignant skull-based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment

View Full Filing

View this 10-K filing on SEC EDGAR